Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Exploring the Feasibility of an Exercise and Noninvasive Brain Stimulation Intervention in Breast Cancer Survivors

7 mai 2026 mis à jour par: Florida Atlantic University
The purpose of this study is to assess the feasibility of a 4-week intervention combining exercise and transcranial alternating current stimulation (Ex+tACS) in breast cancer survivors who report experiencing cancer-related cognitive impairment. Feasibility will be assessed by measuring participant retention, adherence, satisfaction with the intervention, and safety. The researchers will also examine pre-to-post intervention changes in attention, executive function, working memory, perceived cognitive function, and physical function before, after, and four weeks post intervention completion in the Ex+tACS group compared to a control group who will receive exercise and a placebo tACS condition (CON).

Aperçu de l'étude

Description détaillée

Breast cancer is one of the most common forms of cancer among women in the United States. Although advances in cancer treatments have led to improved survival rates, breast cancer survivors must contend with the negative side effects from the cancer and its treatments. One of the most common and highly distressing treatment side effects is cancer-related cognitive impairment (CRCI), which is characterized by losses in memory, attention, processing speed, and executive function, which make daily tasks such as recalling information, organizing daily routines, concentrating, and multitasking more challenging. Findings from previous studies support aerobic exercise training as an effective strategy for improving cognitive function. In addition, non-invasive brain stimulation (NIBS), a technique in which electrodes are applied to the skin to noninvasively stimulate specific regions of the brain, has also been found to be a safe and effective approach for improving cognitive outcomes. Among various NIBS techniques, transcranial alternating current stimulation (tACS), which delivers current to the brain in an alternating pattern, may be a promising strategy for improving cognitive outcomes. Few studies have explored these approaches in breast cancer survivors, and to our knowledge, the combination of exercise and tACS (Ex+tACS) has not been explored.

This study will assess the feasibility of a 4-week Ex+tACS intervention in breast cancer survivors who report cancer-related cognitive impairment. Researchers will also examine changes in attention, executive function, working memory, perceived cognitive function, and physical function before, after, and four weeks post intervention completion in the Ex+tACS group compared to a control group who will receive exercise and a placebo tACS condition (CON).

Type d'étude

Interventionnel

Inscription (Estimé)

40

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Ashley L Artese, PhD
  • Numéro de téléphone: 856-534-8926
  • E-mail: aartese@fau.edu

Lieux d'étude

    • Florida
      • Boca Raton, Florida, États-Unis, 33431
        • Recrutement
        • Florida Atlantic University
        • Contact:
          • Ashley L Artese, PhD
          • Numéro de téléphone: 856-534-8926
          • E-mail: aartese@fau.edu

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • Breast cancer survivors (≥18 years) will be eligible to participate if the following inclusion criteria is met:
  • Diagnosed non-metastatic breast cancer (stages 0-3)
  • Completed primary breast cancer treatment (surgery, chemotherapy, radiation) for at least 3 months
  • Self-reported cognitive impairment after cancer treatment

Exclusion Criteria:

  • Current participation in aerobic exercise for ≥60 min/wk
  • Contraindication or impairment that precludes the potential participant from exercise as defined by the American College of Sports Medicine
  • The presence of serious medical illnesses, metal implants, previous brain trauma, epilepsy or history of seizures, previous surgery to the head or spinal cord, or skin problems at the forehead area where the tACS electrodes will be applied
  • Uncontrolled cardiovascular disease
  • Functional impairments or physical condition that would make exercise unsafe
  • Metastatic cancer or diagnosis of a different cancer (excluding melanoma) within the past 5 years
  • Contraindication to exercise a defined by the American College of Sports Medicine

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Soins de soutien
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Intervention Arm
The Exercise + transcranial alternating current stimulation (Ex+tACS) group will complete a four-week intervention consisting of 3 days/week of 30 minutes of aerobic exercise on a treadmill at a sustained moderate intensity, immediately followed by 15 min of tACS. During tACS, 6Hz alternating current stimulation will be administered to participants' prefrontal cortex (forehead region) using a tACS while the participant completes the AX Continuous Performance Test (AX-CPT).
The Ex+tACS group will complete a four-week intervention consisting of 3 days/week of 30 minutes of aerobic exercise on a treadmill at a sustained moderate intensity, immediately followed by 15 min of tACS while completing the AX Continuous Performance Test (AX-CPT).
Comparateur factice: Control
The Sham Comparator group will complete 30 minutes of aerobic exercise on the treadmill followed by the Sustained Attention-Continuous Performance Task (AX-CPT) with a sham transcranial alternating current stimulation (tACS) condition. The same procedures will be followed regarding the tACS, but stimulation will only last one minute, ramping up and down at the beginning and end of the 15-minute period, simulating the periodic tingling sensation that are reported with tACS.
The Control (CON) group will complete 30 minutes of aerobic exercise on the treadmill followed by the Sustained Attention-Continuous Performance Task (AX-CPT) with a sham tACS condition. After each session, both the EX+tACS and control participants will complete a questionnaire regarding experience with tACS.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Adherence
Délai: From baseline to the end of the 4-week intervention
Adherence will be calculated based on the percentage of prescribed sessions attended and percentage of participants who complete the prescribed exercise and tACS sessions.
From baseline to the end of the 4-week intervention
Retention
Délai: From baseline to the end of the 4-week intervention
Retention will be determined by the number of enrolled breast cancer survivors who participate in the four-week intervention and complete post assessments.
From baseline to the end of the 4-week intervention
Acceptability
Délai: From baseline to the end of the 4-week intervention
Acceptability will be determined by the percentage of participants who report satisfaction with the intervention.
From baseline to the end of the 4-week intervention
Safety (Adverse Events)
Délai: From baseline to the end of the 4-week intervention
Safety (<5% of serious adverse events) will be determined by the percentage of participants experiencing a serious adverse event related to the program.
From baseline to the end of the 4-week intervention

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Sustained attention
Délai: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in sustained attention, measured by performance on the AX-Continuous Performance Test (AX-CPT).
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Executive function
Délai: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in executive function, measured by performance (time) on the Trail Making Test Part A (TMT-A) and Part B (TMT-B).
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Inhibitory control
Délai: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in inhibitory control, measured by performance on the Flanker Compatibility Task.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Working Memory
Délai: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in working memory, measured by performance on the N-back and Backwards Counting tasks.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Subjective Cognition
Délai: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in subjective cognition, measured by the Functional Assessment Cancer Therapy-Cognition (FACT-COG)
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Physical Function
Délai: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in lower body physical function, measured by the 30-second chair stand.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Cardiorespiratory endurance
Délai: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in cardiorespiratory fitness, measured by the six-minute walk test.
Baseline, within 2 weeks following the intervention, and 4-week follow-up

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Body fat percentage
Délai: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in body fat percentage measured via bioelectrical impedance analysis using the BIA-ACC (BioTekna) device.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Learning and Memory
Délai: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in learning and memory, assessed by the California Verbal Learning Test.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Quality of Life (FACT-B)
Délai: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in quality of life, measured by the Functional Assessment of Cancer Therapy - Breast. Scores range from 0-148, with higher scores indicating better quality of life.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Fatigue (FACIT-F)
Délai: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in fatigue, measured by the Functional Assessment of Chronic Illness Therapy-Fatigue. Scores range from 0-52, with higher scores indicating less fatigue.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Perceived exercise benefits and barriers
Délai: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in perceived benefits and barriers to exercise, measured by the Exercise Benefits/Barriers Scale (EBBS). Benefit scores range from 29-116, with higher scores indicating greater perceived benefits. Barrier scores range from 14-56, with higher scores indicating greater perceived barriers.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Physical Function (Short Physical Performance Battery)
Délai: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in physical function, assessed using the Short Physical Performance Battery. Scores range from 0-12, with higher scores indicating better physical function.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Muscle Power
Délai: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in lower body muscle power, measured by a single sit-to-stand using the Tendo Power Analyzer.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Grip strength
Délai: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in grip strength, measured using a hand-held grip strength dynamometer
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Upper body physical function
Délai: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in upper body physical function, measured by the 30-second arm curl test.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Fall Risk
Délai: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in fall risk, measured by the Falls Efficacy Scale. Scores range from 16-64, with higher scores indicating greater fall risk.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Physical Activity
Délai: Baseline, within 2 weeks following the intervention, and 4-week follow-up
Researchers will assess pre- to post-intervention changes in physical activity, measured by an accelerometer.
Baseline, within 2 weeks following the intervention, and 4-week follow-up
Skeletal Muscle
Délai: Baseline, within two weeks following the intervention, 4-week follow-up
Description: Researchers will assess pre- to post-intervention changes in skeletal muscle (kg) measured via bioelectrical impedance analysis using the BIA-ACC (BioTekna) device
Baseline, within two weeks following the intervention, 4-week follow-up

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

7 janvier 2026

Achèvement primaire (Estimé)

1 janvier 2027

Achèvement de l'étude (Estimé)

1 janvier 2027

Dates d'inscription aux études

Première soumission

30 janvier 2026

Première soumission répondant aux critères de contrôle qualité

7 mai 2026

Première publication (Réel)

14 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

14 mai 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

7 mai 2026

Dernière vérification

1 mai 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

The dissemination plan includes sharing de-identified data for external researchers.

Délai de partage IPD

IPD will be available at the time of manuscript acceptance and publishing. A published manuscript is planned for 2027.

Critères d'accès au partage IPD

Any external researcher will be able to access de-identified, non, PHI, individual participant data as part of the journal's supplementary information.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • CIF

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner